Table 1.
Characteristics of pulmonary hypertension patients stratified by eGFR
| Factor | Overall (n=1088) | eGFR≥60 ml/min per 1.73 m2 (n=700) | eGFR=30–59 ml/min per 1.73 m2 (n=340) | eGFR=15–29 ml/min per 1.73 m2 (n=48) | P Value |
|---|---|---|---|---|---|
| Age, mean±SD (yr) | 60.1±15.2 | 56.4±14.9 | 66.5±13.4 | 69.2±11.7 | <0.001a |
| Sex, no. (%) | 0.50b | ||||
| Women | 716 (65.8) | 462 (66.0) | 219 (64.4) | 35 (72.9) | |
| Men | 372 (34.2) | 238 (34.0) | 121 (35.6) | 13 (27.1) | |
| Race, no. (%) | 0.23b | ||||
| White | 877 (80.6) | 556 (79.4) | 281 (82.6) | 40 (83.3) | |
| African American | 173 (15.9) | 121 (17.3) | 44 (12.9) | 8 (16.7) | |
| Other | 38 (3.5) | 23 (3.3) | 15 (4.4) | 0 (0.0) | |
| Diabetes, no. (%) | 283 (26.0) | 152 (21.7) | 113 (33.2) | 18 (37.5) | <0.001b |
| Hypertension, no. (%) | 515 (47.3) | 287 (41.0) | 192 (56.5) | 36 (75.0) | <0.001b |
| CHF (EF<40%), no. (%)c | 71 (7.2) | 37(5.8) | 30 (9.6) | 4 (9.3) | 0.08b |
| BMI, mean±SD (kg/m2)c | 31.0±9.0 | 30.7±9.0 | 31.9±9.0 | 29.5±7.0 | 0.06a |
| WHO class of PH | <0.001b | ||||
| I (PAH) | 552 (50.7) | 374 (53.4) | 158 (46.5) | 20 (41.7) | |
| II (PVH) | 279 (25.6) | 150 (21.4) | 111 (32.6) | 18 (37.5) | |
| III (PH lung disease) | 116 (10.7) | 74 (10.6) | 39 (11.5) | 3 (6.3) | |
| IV (PH CTED) | 57 (5.2) | 47 (6.7) | 10 (2.9) | 0 (0.0) | |
| V (miscellaneous) | 84 (7.7) | 55 (7.9) | 22 (6.5) | 7 (14.6) | |
| Albumin, mean±SD (g/dl)c | 3.9±0.6 | 3.9±0.6 | 3.8±0.5 | 3.8±0.6 | 0.02a |
| Hemoglobin, mean±SD (g/dl)c | 13.6±2.3 | 13.8±2.3 | 13.3±2.2 | 11.9±1.9 | <0.001a |
| BNP, median (P25, P75)c | 183.0 (59.0, 494.0) | 130.0 (44.0, 361.0) | 288.0 (105.0, 606.0) | 640.0 (194.0, 1608.0) | <0.001d |
| BUN, mean±SD (mg/dl)c | 22.6±14.8 | 16.6±6.6 | 30.9±15.7 | 51.2±26.8 | <0.001a |
| Creatinine, mean±SD (mg/dl) | 1.05±0.47 | 0.82±0.17 | 1.3±0.29 | 2.5±0.80 | <0.001a |
| eGFR, mean±SD (ml/min per 1.73 m2) | 72.3±28.5 | 87.7±22.9 | 47.4±8.3 | 23.4±5.1 | <0.001a |
| Sodium, mean±SD (mmol/L)c | 138.9±3.7 | 139.0±3.5 | 138.8±4.0 | 138.8±3.4 | 0.66a |
| Percent pred. 6-min walk, mean±SDc | 56.7±20.9 | 57.6±20.4 | 55.1±21.7 | 50.4±24.0 | 0.13a |
| Heart rate, mean±SDc | 80.9±15.4 | 82.0±15.2 | 79.0±15.8 | 78.2±15.2 | 0.01a |
| Systolic BP, mean±SD (mmHg)c | 131.3±24.7 | 128.9±22.6 | 135.7±27.5 | 136.9±28.8 | <0.001a |
| Diastolic BP, mean±SD (mmHg)c | 76.8±14.0 | 77.2±13.6 | 76.3±15.0 | 74.0±14.3 | 0.27a |
| Mean BP, mean±SD (mmHg)c | 95.2±15.8 | 94.8±15.0 | 95.9±17.2 | 94.6±18.1 | 0.57a |
| ACEI/ARBs, no. (%)c | 335 (31.2) | 190 (27.5) | 128 (38.1) | 17 (36.2) | 0.002b |
| Diuretics, no. (%) | 716 (66.7) | 419 (60.6) | 261 (77.7) | 36 (76.6) | <0.001b |
CHF, congestive heart failure; EF, ejection fraction; BMI, body mass index; WHO, World Health Organization; PH, pulmonary hypertension; PAH, pulmonary arterial hypertension; PVH, pulmonary venous hypertension; CTED, chronic thromboembolic disease; BNP, brain natriuretic peptide; P, percentile; pred., predicted; ACEI/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker.
ANOVA.
Pearson's chi-squared test.
Data not available for all patients. Missing values: CHF (EF<40%)=96, BMI=19, albumin=13, hemoglobin=2, BNP=169, BUN=129, sodium=128, percent pred 6-min walk=347, heart rate=173, systolic BP=87, diastolic BP=92, mean BP=93, medications=14.
Kruskal–Wallis test.